Clinical Trial Search

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants

Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Event-free Survival — 16 Participants

Primary: The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma — 62.7 Percentage…

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Progression-free Survival — 72 Percent

Primary: Objective Tumor Response — 0 participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients

Primary: Objective Response Rate — 2; 0 Patients

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Efficacy: Complete Response Rate (CRR) — 9.5 percentage of patients

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants